BR0200782A - Compostos para o tratamento da isquemia - Google Patents

Compostos para o tratamento da isquemia

Info

Publication number
BR0200782A
BR0200782A BR0200782-7A BR0200782A BR0200782A BR 0200782 A BR0200782 A BR 0200782A BR 0200782 A BR0200782 A BR 0200782A BR 0200782 A BR0200782 A BR 0200782A
Authority
BR
Brazil
Prior art keywords
ischemia
agonists
compounds
treatment
formula
Prior art date
Application number
BR0200782-7A
Other languages
English (en)
Inventor
Michael Paul Deninno
Hiroko Masamune
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR0200782A publication Critical patent/BR0200782A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

"COMPOSTOS PARA O TRATAMENTO DA ISQUEMIA". Estão descritos os agonistas de A~ 3~ de Fórmula I, bem como os métodos de utilização de tais agonistas de A~ 3~ e as composições farmacêuticas contendo tais agonistas de A~ 3~. Fórmula I Os agonistas de A~ 3~ são úteis para a redução do dano ao tecido resultante da isquemia ou hipoxia do tecido.
BR0200782-7A 2001-03-16 2002-03-13 Compostos para o tratamento da isquemia BR0200782A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27641101P 2001-03-16 2001-03-16

Publications (1)

Publication Number Publication Date
BR0200782A true BR0200782A (pt) 2003-01-07

Family

ID=23056556

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0200782-7A BR0200782A (pt) 2001-03-16 2002-03-13 Compostos para o tratamento da isquemia

Country Status (6)

Country Link
US (2) US20030055021A1 (pt)
EP (1) EP1241176A1 (pt)
JP (1) JP2002322193A (pt)
BR (1) BR0200782A (pt)
CA (1) CA2376738A1 (pt)
MX (1) MXPA02002971A (pt)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2474337A1 (en) * 2002-01-25 2003-07-31 Muscagen Limited Compounds useful as a3 adenosine receptor agonists
US7414036B2 (en) 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists
KR20040036417A (ko) * 2002-10-25 2004-04-30 정낙신 항암 활성을 갖는 티오뉴클레오시드 유도체 및 이를함유하는 약학적 조성물
JP2006517807A (ja) * 2002-12-30 2006-08-03 パーデュー・リサーチ・ファウンデーション 中枢神経系の損傷の治療方法
CA2515368A1 (en) * 2003-02-13 2004-08-26 Luciano Rossetti Regulation of food intake and glucose production by modulation of long-chain fatty acyl-coa levels in the hypothalamus
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
GB0317951D0 (en) * 2003-07-31 2003-09-03 Trigen Ltd Compounds
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
KR101267202B1 (ko) * 2004-05-26 2013-05-24 이노텍 파마슈티컬스 코포레이션 아데노신 ａ1 수용체 아고니스트로서의 퓨린 유도체 및 이것의 사용 방법
WO2006031505A1 (en) * 2004-09-09 2006-03-23 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Purine derivatives as a3 and a1 adenosine receptor agonists
JP5011112B2 (ja) * 2004-09-20 2012-08-29 イノテック ファーマシューティカルズ コーポレイション プリン誘導体を含有する炎症性疾患の治療用医薬
WO2006041922A2 (en) * 2004-10-08 2006-04-20 Dara Biosciences, Inc. Agents and methods for administration to the central nervous system
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
US20070026079A1 (en) * 2005-02-14 2007-02-01 Louis Herlands Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
EP2281813A1 (en) 2005-08-08 2011-02-09 Pulmagen Therapeutics (Synergy) Limited Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses
JP5006330B2 (ja) 2005-10-21 2012-08-22 ノバルティス アーゲー Ｉｌ１３に対するヒト抗体および治療的使用
JP5203214B2 (ja) * 2005-11-30 2013-06-05 イノテック ファーマシューティカルズ コーポレイション プリン化合物およびその使用方法
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
US20090286779A1 (en) 2006-09-29 2009-11-19 Novartis Ag Pyrazolopyrimidines as lipid kinase inhibitors
RU2009120389A (ru) 2006-10-30 2010-12-10 Новартис АГ (CH) Гетероциклические соединения в качестве противовоспалительных агентов
EA017573B1 (ru) 2007-12-14 2013-01-30 Пульмаджен Терапьютикс (Эсме) Лимитед Производные индол-1-илуксусной кислоты и их терапевтическое применение
US8431578B2 (en) 2008-01-11 2013-04-30 Novartis Ag Organic compounds
WO2010011824A1 (en) * 2008-07-25 2010-01-28 Concert Pharmaceuticals, Inc. Novel xanthine compounds
PL2391366T3 (pl) 2009-01-29 2013-04-30 Novartis Ag Podstawione benzimidazole do leczenia gwiaździaków
MA33128B1 (fr) 2009-02-17 2012-03-01 Chiesi Farma Spa Derives de triazolopyridine utilises comme inhibiteurs de la p38 map kinase
GB0902648D0 (en) 2009-02-17 2009-04-01 Argenta Discovery Ltd Pharmaceutical compounds and compositions
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EP2464649A1 (en) 2009-08-12 2012-06-20 Novartis AG Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
EA026693B1 (ru) 2009-08-17 2017-05-31 Интелликайн ЭлЭлСи Производные бензоксазола и бензотиазола в качестве ингибиторов pi3-киназы
IN2012DN01453A (pt) 2009-08-20 2015-06-05 Novartis Ag
KR20120115344A (ko) 2010-01-11 2012-10-17 이노텍 파마슈티컬스 코포레이션 안압을 감소시키는 혼합물, 키트 및 방법
BR112012023749A2 (pt) 2010-03-26 2016-08-23 Inotek Pharmaceuticals Corp método para reduzir a pressão intraocular em humanos utilizando n6-ciclopentiladenosina (cpa), derivados de cpa ou pró-fármacos desses
GB201009731D0 (en) 2010-06-10 2010-07-21 Pulmagen Therapeutics Inflamma Kinase inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012107500A1 (en) 2011-02-10 2012-08-16 Novartis Ag [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
WO2012116217A1 (en) 2011-02-25 2012-08-30 Irm Llc Compounds and compositions as trk inhibitors
AU2012310168B2 (en) 2011-09-15 2015-07-16 Novartis Ag 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase
JP6130391B2 (ja) 2011-11-23 2017-05-17 インテリカイン， エルエルシー Ｍｔｏｒ阻害剤を使用する強化された治療レジメン
PL2788349T3 (pl) 2011-12-09 2017-04-28 Chiesi Farmaceutici S.P.A. Inhibitory kinaz
EP2788345B1 (en) 2011-12-09 2020-06-10 Chiesi Farmaceutici S.p.A. Derivatives of 4-hydroxy-1,2,3,4-tetrahydronaphtalen-1-yl urea and their use in the treatment of, inter alia, diseases of the respiratory tract
EP2788348B1 (en) 2011-12-09 2016-10-19 Chiesi Farmaceutici S.p.A. Kinase inhibitors
MX2014009086A (es) 2012-01-26 2015-06-05 Inotek Pharmaceuticals Corp Polimorfos anhidros de nitrato de [ (2r,3s,4r,5r) -5- (6- (ciclopentilamino) -9h-purin-9-il) -3,4-dihidroxitetra-hidrofuran- 2-il) ] metilo y procesos para su preparación.
WO2013149581A1 (en) 2012-04-03 2013-10-10 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
WO2014152723A1 (en) 2013-03-15 2014-09-25 Inotek Pharmaceuticals Corporation Ophthalmic formulations
JP2016512835A (ja) 2013-03-15 2016-05-09 インテリカイン， エルエルシー キナーゼ阻害剤の組み合わせ及びそれらの使用
WO2014195402A1 (en) 2013-06-06 2014-12-11 Chiesi Farmaceutici S.P.A. Kinase inhibitors
SG11201601707PA (en) 2013-09-05 2016-04-28 Hoffmann La Roche Triazolopyridine compounds, compositions and methods of use thereof
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
WO2016016822A1 (en) 2014-07-31 2016-02-04 Novartis Ag Combination therapy
WO2016139212A1 (en) 2015-03-04 2016-09-09 F. Hoffmann-La Roche Ag Triazolopyridine compounds and methods of use thereof
TW201720828A (zh) 2015-11-23 2017-06-16 赫孚孟拉羅股份公司 治療性化合物及組合物以及其使用方法
WO2017108737A1 (en) 2015-12-23 2017-06-29 Chiesi Farmaceutici S.P.A. 1-(3-tert-butyl-phenyl)-3-(4-([1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro- naphthalen-1-yl)-urea derivatives and their use as p38 mapk inhibitors
AR107164A1 (es) 2015-12-23 2018-03-28 Chiesi Farm Spa INHIBIDORES DE QUINASA p38
AR107163A1 (es) 2015-12-23 2018-03-28 Chiesi Farm Spa Inhibidores de quinasa
JP7034942B2 (ja) 2016-05-05 2022-03-14 エフ．ホフマン－ラ ロシュ アーゲー ピラゾール誘導体、その組成物及び治療的使用
AU2017324281A1 (en) 2016-09-06 2019-03-21 F. Hoffmann-La Roche Ag 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-A]pyridinyl compounds, compositions and methods of use thereof
WO2018122212A1 (en) 2016-12-29 2018-07-05 F. Hoffmann-La Roche Ag Pyrazolopyrimidine compounds and methods of use thereof
WO2018166993A2 (en) 2017-03-14 2018-09-20 F. Hoffmann-La Roche Ag Pyrazolochlorophenyl compounds, compositions and methods of use thereof
WO2018215390A1 (en) 2017-05-22 2018-11-29 F. Hoffmann-La Roche Ag Therapeutic compounds and compositions, and methods of use thereof
BR112019024322A2 (pt) 2017-05-22 2020-06-16 F. Hoffmann-La Roche Ag Compostos e composições terapêuticos e métodos de uso dos mesmos
US10364245B2 (en) 2017-06-07 2019-07-30 Chiesi Farmaceutici S.P.A. Kinase inhibitors
CN111587250A (zh) 2018-01-15 2020-08-25 豪夫迈·罗氏有限公司 作为jak抑制剂的吡唑并嘧啶化合物
CN114026096A (zh) 2019-06-18 2022-02-08 豪夫迈·罗氏有限公司 四唑取代的吡唑并嘧啶类jak激酶抑制剂及其用途
MA56518A (fr) 2019-06-18 2022-04-27 Hoffmann La Roche Inhibiteurs de sulfone pyrazolopyrimidine de jak kinases et leurs utilisations
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2852505A (en) * 1955-10-31 1958-09-16 American Cyanamid Co Aminodeoxyglycosidopurines
US2852506A (en) * 1955-10-31 1958-09-16 American Cyanamid Co Method of preparing aminodeoxyglycosidopurines
US5817760A (en) * 1992-03-13 1998-10-06 Merck & Co., Inc. Human A3 adenosine receptors
US5688774A (en) * 1993-07-13 1997-11-18 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists
ATE206432T1 (de) * 1993-07-13 2001-10-15 Nasa A3 -adenosin -rezeptor agonisten
EP0704215A3 (en) * 1994-06-02 1998-04-01 Takeda Chemical Industries, Ltd. Inhibitor of vascular permeability enhancer
US6376472B1 (en) * 1996-07-08 2002-04-23 Aventis Pharmaceuticals, Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
US5789416B1 (en) * 1996-08-27 1999-10-05 Cv Therapeutics Inc N6 mono heterocyclic substituted adenosine derivatives
CO5180581A1 (es) * 1999-09-30 2002-07-30 Pfizer Prod Inc Compuestos para el tratamiento de la isquemia ciones farmaceuticas que los contienen para el tratamiento de la isquemia

Also Published As

Publication number Publication date
US20030055021A1 (en) 2003-03-20
US20050171049A1 (en) 2005-08-04
MXPA02002971A (es) 2003-07-14
JP2002322193A (ja) 2002-11-08
CA2376738A1 (en) 2002-09-16
EP1241176A1 (en) 2002-09-18

Similar Documents

Publication Publication Date Title
BR0200782A (pt) Compostos para o tratamento da isquemia
BR0014384A (pt) Compostos para o tratamento da isquémia
BR0007589A (pt) Inibidores da proliferação de células
BR0116402A (pt) Derivados de tetrahidropiridina, sua preparação e sua utilização como inibidores de proliferação celular
BR9914221B1 (pt) Derivados de glicopeptídeos e composições farmacêuticas contendo os mesmos
ATE433447T1 (de) Pyrimiidinverbindungen
SE0101387D0 (sv) Novel compounds
NO20003233L (no) 4-hydroksykinolin-3-karboksamider og hydrazider som antivirale midler
BR0312464A (pt) Inibidores de tirosina quinases
BR0209127A (pt) compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
DE60204452D1 (de) Pyrazolo[1,5]pyridinderivate
BRPI0414533A (pt) composto, composição farmacêutica, e, métodos para inibir um hsp90 e para tratar um indivìduo tendo um distúrbio mediado por hsp90
IS6658A (is) Ný efnasambönd
BR0209129A (pt) Compostos, composições farmacêuticas, métodos para tratamento de dores, métodos para modulação de uma resposta farmacológica e usos de compostos
DE60214179D1 (de) IMIDAZOi1,2-AöPYRIDIN-DERIVATE ZUR PROPHYLAXE UND BEHANDLUNG VON HERPES-INFEKTIONEN
TR200200883T2 (tr) 2-ikameli 1,1-bifenil-2-karbonamidler, imalat yöntemleri, ilaç olarak kullanılmaları
MXPA04004601A (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos.
ES2243579T3 (es) Derivados de pirazolopirideno.
SE9904108D0 (sv) Nya föreningar
DE60045508D1 (de) Dalda-analoge und ihre verwendung
ATE364043T1 (de) Pyrazolo-pyridine für die behandlung von herpes- ansteckungen
SE9804212D0 (sv) Compounds
BR0209128A (pt) Compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
ATE253359T1 (de) Antithrombotische mittel
BR0308601A (pt) inibidores de carboxipeptidase b de plasma

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1980 DE 16/12/2008.